UZ Leuven

Recently closed projects/recent gesloten projecten/projets récemment fermés/kürzlich geschlossene Projekte 

Phase II trial of radiotherapy plus Panitumumab compared to chemoradiotherapy in subjects with unresected, locally advanced squamous cell carcinoma of the head and neck. Panitumumab is a human monoclonal anti-EGF receptor antibody. Study group/sponsor: Amgen. Contact: Prof. P. Clement (PI: Prof. S. Nuyts)

Phase II study of BIBW 2992 versus cetuximab (Erbitux) in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC) after failure of platinum-containing therapy with a cross-over period for progressing patients. BIBW 2992 is a pan HER inhibitor; Cetuximab is a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR). Study group/sponsor: Boehringer Ingelheim. Contact: Prof. P. Clement.

Trial with Zalutumumab in combination with chemo-radiation in patients with advanced squamous cell carcinoma of the head and neck. Zalutumumab is an anti-EGF receptor human monoclonal antibody. Study group/sponsor: Genmab. Contact: Prof. P. Clement (PI: Prof. S. Nuyts). 

Ongoing projects/lopende projecten/projets actifs/laufende Projekte 

Zalutumumab in combination with best supportive care versus best supportive care, in patients with non-curable squamous cell carcinoma of the head & neck. Zalutumumab is a human monoclonal anti-EGF receptor antibody. For patients who have failed standard platinum-based chemotherapy. Study group/sponsor: Genmab. Contact: Prof. P. Clement.

Phase III trial of chemotherapy with or without Panitumumab in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck. Panitumumab is a human monoclonal anti-EGF receptor antibody. Study group/sponsor: Amgen. Contact: Prof. P. Clement. 

Phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies. Cetuximab is a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR). Study group/sponsor: EORTC. Contact: Prof. P. Clement.

Randomized phase I/II study of Cilengitide to evaluate safety and efficacy of the combination of different regimens of Cilengitide added to Cisplatin, 5-FU and Cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck. Cilengitide is an integrin inhibitor; Cisplatin is a platinum based chemotherapy drug; 5-FU is a pyrimidine analog; Cetuximab is a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR). Study group/sponsor: Merck.

An open-label, multi-center, phase I/II trial investigating the pharmacokinetic profile of Zalutumumab in non-curable patients with SCCHN. Zalutumumab is a human monoclonal epidermal growth factor receptor antibody. Study group/sponsor: Genmab. Contact: Prof. P. Clement

Planned projects/geplande projecten/projets en développement/geplante Projekte 

Randomized, phase III trial on postoperative chemoradiation in combination with anti-EGFR-antibody versus postoperative chemoradiation in head and neck squamous cell carcinomas (HNSCC) with high risk of locoregional recurrence. Study group/sponsor: EORTC. Contact: Prof. S. Nuyts

Phase Ib trial of multiple-ascending doses of EMD 1201081 in combination with 5FU/cisplatin and cetuximab in first-line subjects with recurrent/metastatic squamous cell carcinoma of the head and neck. Study group/sponsor: Merck AG. Contact: Prof. P. Clement

• Print
• Stuur door